Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

doi:10.18632/oncotarget.11891

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Oncotarget - 18 Oct 2016

Darb-Esfahani Silvia, Denkert Carsten, Stenzinger Albrecht, Salat Christoph, Sinn Bruno, Schem Christian, Endris Volker, Klare Peter, Schmitt Wolfgang, Blohmer Jens-Uwe, Weichert Wilko, Möbs Markus, Tesch Hans, Kümmel Sherko, Sinn Peter, Jackisch Christian, Dietel Manfred, Reimer Toralf, Loi Sherene, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Loibl Sibylle

Abstract excerpt

BACKGROUND: TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. METHODS: 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and triple negative breast cancer (TNBC) were subjected to Sanger sequencing of exons 5-8 of the TP53 gene. TP53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Bridged-Ring Compounds

Share to Carboplatin

Share to Lapatinib

Share to Neoadjuvant Therapy

Share to Taxoids

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 27611952
DOI: 10.18632/oncotarget.11891
PMCID: PMC5356512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.PMID 27611952Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Semantic proximity Read ↗

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.Semantic proximity Read ↗

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.Semantic proximity Read ↗

TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.Semantic proximity Read ↗

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.Semantic proximity Read ↗

Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up DateSemantic proximity Read ↗

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.Semantic proximity Read ↗

TP53 mutations predict poor breast cancer-specific survival in ER-positive breast cancer patients.Semantic proximity Read ↗

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Semantic proximity Read ↗

Integrated Analysis of p53 Immunohistochemical Expression and TP53 Sequencing for Prognostic Assessment of Triple Negative Breast Cancer After Neoadjuvant ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.